

Elisa Roca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1257136/publications.pdf>

Version: 2024-02-01

55
papers

1,245
citations

331538

21
h-index

395590

33
g-index

55
all docs

55
docs citations

55
times ranked

2368
citing authors

#	ARTICLE	IF	CITATIONS
1	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. <i>Neuroendocrinology</i> , 2021, 111, 475-489.	1.2	19
2	The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. <i>Oral Oncology</i> , 2021, 114, 105128.	0.8	11
3	CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer. <i>Radiologia Medica</i> , 2021, 126, 786-794.	4.7	46
4	Rate of venous thromboembolism and atrial fibrillation in a real-world case series of advanced cancer patients: the CaTEV Study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 444-452.	0.6	3
5	Cancer of the Adrenal Gland. <i>UNIPA Springer Series</i> , 2021, , 933-955.	0.1	0
6	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3.	1.1	19
7	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020, 9, 1828.	1.8	13
8	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	1.4	12
9	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020, 37, 1145-1155.	1.3	102
10	Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer. <i>Cells</i> , 2020, 9, 291.	1.8	18
11	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019, 134, 121-126.	0.9	4
12	Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study. <i>European Journal of Radiology</i> , 2019, 118, 251-256.	1.2	11
13	Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy. <i>Radiologia Medica</i> , 2019, 124, 877-886.	4.7	42
14	Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. <i>Endocrine</i> , 2019, 64, 724-726.	1.1	5
15	Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 729-742.	1.4	7
16	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , 2019, 120, 57-62.	2.9	68
17	Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. <i>Lung Cancer</i> , 2019, 127, 12-18.	0.9	40
18	Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 458-467.	0.3	22

#	ARTICLE	IF	CITATIONS
19	Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 165-175.e2.	0.9	41
20	How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 25-34.	1.0	11
21	IFN- γ in advanced well-differentiated neuroendocrine tumors: the neglected drug?. <i>Future Oncology</i> , 2018, 14, 897-899.	1.1	1
22	Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma. <i>Supportive Care in Cancer</i> , 2018, 26, 2929-2935.	1.0	6
23	Palbociclib inhibits proliferation of human adrenocortical tumor cells. <i>Endocrine</i> , 2018, 59, 213-217.	1.1	28
24	Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions. <i>Clinical Respiratory Journal</i> , 2018, 12, 1011-1016.	0.6	20
25	Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma. <i>Endocrine</i> , 2018, 61, 169-172.	1.1	21
26	Efficacy of topic steroids in the management of asthma and chronic obstructive pulmonary disease in advanced non-small cell lung cancer patients during treatment with nivolumab. <i>Minerva Respiratory Medicine</i> , 2018, 57, .	0.1	0
27	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	3.4	38
28	CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). <i>European Journal of Radiology</i> , 2018, 109, 130-135.	1.2	33
29	Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study. <i>Oncology</i> , 2018, 94, 10-15.	0.9	19
30	Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1125-1133.	1.1	34
31	Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. <i>In Vivo</i> , 2018, 32, 159-164.	0.6	14
32	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. <i>Translational Cancer Research</i> , 2018, 8, S16-S22.	0.4	0
33	The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma. <i>Translational Cancer Research</i> , 2018, 7, S506-S509.	0.4	0
34	Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice. <i>Annals of Translational Medicine</i> , 2018, 6, 369-369.	0.7	0
35	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. <i>Bone</i> , 2017, 97, 147-152.	1.4	33
36	When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1487-1488.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Topoisomerase 2 α and thymidylate synthase expression in adrenocortical cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 319-327.	1.6	24
38	Regression of advanced neuroendocrine tumors among patients receiving placebo. <i>Endocrine-Related Cancer</i> , 2017, 24, L13-L16.	1.6	5
39	Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2017, 59, 117-122.	3.4	61
40	Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity. <i>Pharmacology</i> , 2017, 100, 261-268.	0.9	14
41	MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. <i>European Journal of Endocrinology</i> , 2017, 177, R231-R248.	1.9	58
42	Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions. <i>Oncotarget</i> , 2016, 7, 3357-3366.	0.8	31
43	Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues. <i>Journal of Clinical Oncology</i> , 2016, 34, 3709-3710.	0.8	3
44	Echocardiographic evaluation in subjects with α 1-antitrypsin deficiency. <i>European Journal of Clinical Investigation</i> , 2015, 45, 949-954.	1.7	11
45	Malignant pleural mesothelioma signs and symptoms. <i>Lung Cancer Management</i> , 2015, 4, 205-209.	1.5	0
46	Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?. <i>Respiration</i> , 2015, 89, 558-564.	1.2	16
47	Positive FDG-PET/CT of the Pleura Twenty Years after Talc Pleurodesis: Three Cases of Benign Talcoma. <i>Respiration</i> , 2014, 87, 243-248.	1.2	34
48	Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy. <i>European Radiology</i> , 2013, 23, 3450-3455.	2.3	107
49	18 F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients. <i>Lung Cancer</i> , 2013, 79, 187-190.	0.9	19
50	Elastic properties of the ascending aorta in patients with α 1-antitrypsin deficiency (Z homozygotes). <i>Heart</i> , 2012, 98, 1354-1358.	1.2	25
51	Effects of CPAP on systemic hypertension in OSAH: A monocentric, observational, cohort study. <i>Respiratory Medicine</i> , 2012, 106, 1329-1334.	1.3	10
52	Malignant Pleural Mesothelioma: From the Bench to the Bedside. <i>Respiration</i> , 2012, 83, 481-493.	1.2	48
53	Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. <i>Journal of Oncology</i> , 2009, 2009, 1-8.	0.6	35
54	Targeted delivery of TNF using NGR-TNF in combination with chemotherapy as an effective and tolerable strategy in a hepatocarcinoma patient. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 43-46.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Detection of serum proteomic profile predictive for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in 1st line chemotherapy responders. Journal of Clinical Oncology, 2008, 26, 8091-8091.	0.8	0